New research shows that people who recovered from Covid-19 disease should only take one dose of the vaccine.
The vaccine that was studied, produced by Pfizer Inc. and BioNTech SE, normally is administered in two doses, 21 days apart, to provide nearly full protection against the novel coronavirus, known as SARS-CoV-2.
Cedars-Sinai research, involving more than 260 individuals, strongly suggests the second dose may not be needed for individuals who have successfully recovered from a prior coronavirus infection.
A single dose of the Pfizer-BioNTech vaccine for individuals who previously had COVID-19 generates an immunologic response similar to that of individuals receiving the two-dose recommended sequence, according to the study published in Nature Medicine. More studies also are needed to determine if the results seen after a single dose of the Pfizer-BioNTech vaccine might also apply to other SARS-CoV-2 vaccines.
“Our findings extend those from smaller studies reported elsewhere and support a potential strategy of providing a single dose of vaccine to persons with a confirmed prior history of coronavirus infection, along with two doses for people not previously infected,” said Susan Cheng, associate professor of Cardiology and director of Public Health Research at the Smidt Heart Institute at Cedars-Sinai. “This approach could maximize the reach of a limited vaccine supply, allowing potentially millions more people to be vaccinated in the US alone.”
“Overall, individuals who had recovered from COVID-19 developed an antibody response after a single vaccine dose that was comparable to that seen after a two-dose vaccination course administered to individuals without prior infections,” said Kimia Sobhani, medical director of the clinical core laboratories and associate professor of Pathology and Laboratory Medicine at Cedars-Sinai.
For their research, the investigators administered surveys to 1,090 healthcare workers in the Cedars-Sinai Health System who had received the Pfizer-BioNTech vaccine. The surveys asked the workers about prior coronavirus infections and any symptoms they might have experienced after being vaccinated.
The healthcare workers also took antibody tests to gauge the response of their immune systems to the vaccinations. Antibody levels were measured at three points in time: before or up to three days after the first dose, within seven to 21 days after the first dose, and within seven to 21 days after the second dose.
Based on the surveys, the research team identified 35 individuals with prior coronavirus infections who had received a single vaccine dose and 228 individuals without prior infection who had received both vaccine doses. Based on the antibody tests, the team found that levels and responses of coronavirus-specific antibodies were similar in both of these groups.
Post-vaccine symptoms were more prominent for those with prior infection after the first dose, but symptomatology was similar between the two groups after the second dose.
They noted that they measured antibody levels only up to 21 days following each vaccine dose and that longer-term follow-up likely would provide additional informative data, especially regarding the duration of the immunity acquired from receiving a single versus double dose of the vaccine.